Immunosuppressants - Hungary

Hungary

Hungary is projected to see a revenue of US$36.34m in the Immunosuppressants market by 2024.
The market is expected to grow at an annual growth rate (CAGR 2024-2029) of 15.21%, resulting in a market volume of US$73.76m by 2029.
When compared globally, United States is expected to generate the highest revenue with US$35,470.00m in 2024.
Hungary has seen a rise in demand for immunosuppressants due to an increase in organ transplant surgeries.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Immunosuppressants in Hungary has been steadily increasing over the past few years.

Customer preferences: Patients in Hungary with autoimmune diseases such as rheumatoid arthritis and lupus have been the primary consumers of Immunosuppressants. Additionally, the rising number of organ transplant surgeries in the country has also contributed to the growth in demand for these drugs.

Trends in the market: One of the major trends in the Immunosuppressants market in Hungary is the increasing availability of generic drugs. This has led to a decrease in prices and an increase in the affordability of these medications for patients. Another trend is the shift towards personalized medicine, where doctors are increasingly tailoring treatment plans to individual patients based on their genetic makeup and other factors.

Local special circumstances: One of the unique factors in the Hungarian market is the government's role in regulating drug prices. The Hungarian government has implemented price controls on certain medications, including Immunosuppressants, in an effort to make healthcare more accessible and affordable for its citizens. This has led to lower prices for these drugs compared to other countries in the region.

Underlying macroeconomic factors: The aging population in Hungary has played a significant role in the growth of the Immunosuppressants market. As the population ages, the prevalence of autoimmune diseases and organ failures increases, leading to higher demand for these drugs. Additionally, the overall growth of the healthcare sector in Hungary has also contributed to the growth of the Immunosuppressants market, as more patients are able to access these medications through the country's healthcare system.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.